SRPT: Rasio kapitalisasi pasar marang pendapatan Sarepta Therapeutics

Simbol lan logo merek Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics, Inc. (SRPT) relies on ultra-precise cryo-logistics for the delivery of gene therapies, operating in a climate of fierce competition with global behemoths for dominance in the rare pathology niche. The fundamental P/S ratio allows for the timely detection of market euphoria, with the metric currently holding at 0.80. The company's monopoly status is secured by patents and FDA approval, which create insurmountable barriers to entry for new players.

SRPT Rasio rega marang pendapatan sarepta.com (04.07.2022 - 17.11.2026)

Rincian metrik lan analitis perusahaan Sarepta Therapeutics Inc (SRPT)

- kuotasi lan prakiraan analis:
- informasi kapitalisasi pasar:
Analisis umum perusahaan:SRPT - Sarepta Therapeutics Inc
Produk mawa merek Sarepta Therapeutics

The P/S multiple compares a business's market value to its generated revenue, allowing for an assessment of the value of each dollar of sales and determining the asset's degree of overboughtness. For Sarepta Therapeutics, Inc. (SRPT), with its monopoly on Duchenne therapy, the price/sales multiple reflects market expectations for the scaling of the Elevidys platform, turning local dips into an indicator of fundamental undervaluation while patent superiority persists.

Karo sapa Sarepta Therapeutics, Inc. saingan

TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Twist Bioscience, Inc. (TWST)|Kapitalisasi marang pendapatan 10x Genomics TXG|Rasio rega marang pendapatan Intellia Therapeutics NTLA|Kapitalisasi marang volume dodolan STOK (Stoke Therapeutics, Inc.)|BLFS - Rasio rega marang pendapatan|Rega marang dodolan Wave Pharma|mazetx.com (MAZE) - Rasio rega marang pendapatan|SION - Koefisien rega marang pendapatan|PRME (Prime Medicine Inc) - Multiplikator P/S|Taysha Gene Therapies, Inc. - Rasio rega marang dodolan|Multiplikator P/S QURE|MGTX: Rasio rega marang dodolan|Rasio rega marang pendapatan REGENXBIO RGNX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan